Budget Justification (not scored)

Extent to which the budget is reasonable, clearly justified, and consistent with the intended use of cooperative agreement funds.

H. Other Requirements

Technical Reporting Requirements

Applicant must provide CDC with an original plus two copies of:

1. Semi-annual progress reports, at the end of the second and fourth quarters of each budget period, no later than 30 days after the end of each of those quarters (a cumulative progress report for the first three quarters of each budget period will be prepared as part of the annual application for continuation funding during the project period).
2. Annual Financial Status Reports, no later than 90 days after the end of each budget period.
3. Final financial status and progress reports, no later than 90 days after the end of the project period.

The following additional requirements are applicable to this program. For a complete description of each, see Attachment 1 in the application kit.

AR–9 Paperwork Reduction Act Requirements
AR–10 Smoke-Free Workplace Requirements
AR–11 Healthy People 2010
AR–12 Lobbying Restrictions

I. Authority and Catalog of Federal Domestic Assistance Number

This program is authorized under Section 317(k) (2) of the Public Health Service Act, 42 U.S.C. 247b(k) (2) as amended. The Catalog of Federal Domestic Assistance number is 93.283.

J. Where to Obtain Additional Information

This and other CDC announcements can be found on the CDC web site at *http://www.cdc.gov.* On CDC's homepage below the ''Spotlights'', click on ''Funding Opportunities'', then on ''Grants and Cooperative Agreements''.

To obtain additional business management information, contact: Juanita D. Crowder, Grants Management Specialist, Grants Management Branch, Procurement and Grants Office, Centers for Disease Control and Prevention, 2920 Brandywine Road, Room 3000, Atlanta, GA 30341–4146, Telephone number: 770–488–2734, E-Mail Address: jcrowder@cdc.gov.

To obtain additional programmatic information, contact: Susan J. Shaw, Division of Public Health Systems Development and Research, Public Health Practice Program Office, Centers for Disease Control and Prevention, 4770 Buford Highway, N.E. (MailStop K–37), Atlanta, GA 30341–3717, Telephone: 770–488–2482, E-Mail: sshaw@cdc.gov.

Dated: March 28, 2001.

John L. Williams,

Director, Procurement and Grants Office, Centers for Disease Control and Prevention.

[FR Doc. 01–8094 Filed 4–2–01; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration for Children and Families

Notice of the Availability of the Fiscal Year 1999 Biennial Report to Congress on the Status of Children in Head Start Programs

AGENCY: Head Start Bureau, ACF, DHHS.

ACTION: Notice.

SUMMARY: The Administration for Children and Families announces the availability of the Biennial Report to Congress on the Status of Children in Head Start Programs. This report is required by Section 650 of the Head Start Act, as amended, which requires the Secretary of Health and Human Services to submit a report to the Congress at least once during every two-year period on the status of children in Head Start programs. The sources of data for this report were the Program Information Report (PIR), the Head Start Cost System (HSCOST) and the Head Start Monitoring and Tracking System (HSMTS).

Head Start is a comprehensive child development program for low-income preschool children and their families. Head Start provides high quality early childhood education, which emphasizes cognitive and language development, social and emotional development, physical and mental Health, nutrition, social services and parental involvement.

FOR FURTHER INFORMATION CONTACT: A copy of the Head Start Biennial Report of the Status of Children in Head Start may be obtained by contacting the Head Start Information and Publication Center, P.O. Box 26417, Alexandria, Virginia, 22313–0417. The fax number is (703) 683–5769. The Information and Publication Center may also re reached by e-mail at *Puborder@headstartinfo.org.*

SUPPLEMENTARY INFORMATION: This Notice is submitted to the **Federal Register** in compliance with Section 650 of the Head Start Act, as amended, which states that upon submitting the Biennial Report on the Status of Children in Head Start Programs to Congress, a notification must be placed in the **Federal Register** announcing that it has been submitted to Congress and is available to the general public.

Dated: March 28, 2001.

James A. Harrell,

Acting Commissioner, Administration on Children, Youth and Families.

[FR Doc. 01–8120 Filed 4–2–01; 8:45 am]

BILLING CODE 4184–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 84N–0102]

Cumulative List of Orphan Drug and Biological Designations

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the availability of the cumulative list of orphan drug and biological designations as of December 31, 2000. FDA has announced the availability of previous lists, which are updated monthly, identifying the drugs and biologicals granted orphan designation under the Federal Food, Drug, and Cosmetic Act (the act).

ADDRESSES: Copies of the cumulative list of orphan drug and biological designations are available from the Dockets Management Branch (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852, and the Office of Orphan Products Development (HF–35), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–3666.

FOR FURTHER INFORMATION CONTACT: James D. Bona or Stephanie Donahoe, Office of Orphan Products Development (HF–35), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–3666.

SUPPLEMENTARY INFORMATION: FDA's Office of Orphan Products Development (OPD) reviews and takes final action on applications submitted by sponsors seeking orphan designation of their drug or biological under section 526 of the act (21 U.S.C. 360bb). In accordance with this section of the act which requires public notification of designations, FDA maintains a